Last $0.19 USD
Change Today +0.004 / 2.21%
Volume 22.5K
AVXL On Other Exchanges
Symbol
Exchange
OTC US
As of 10:08 AM 01/26/15 All times are local (Market data is delayed by at least 15 minutes).

anavex life sciences corp (AVXL) Snapshot

Open
$0.19
Previous Close
$0.18
Day High
$0.19
Day Low
$0.19
52 Week High
03/10/14 - $0.60
52 Week Low
12/1/14 - $0.15
Market Cap
10.1M
Average Volume 10 Days
157.1K
EPS TTM
$-0.29
Shares Outstanding
54.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ANAVEX LIFE SCIENCES CORP (AVXL)

Related News

No related news articles were found.

anavex life sciences corp (AVXL) Related Businessweek News

No Related Businessweek News Found

anavex life sciences corp (AVXL) Details

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, develops drug candidates for the treatment of Alzheimer’s disease, other central nervous system (CNS) diseases, and various cancers. Its lead drug candidates include ANAVEX 2-73, which is in Phase 2a clinical trials for the treatment of Alzheimer’s disease; and ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil for Alzheimer’s disease. The company’s product candidates also include ANAVEX 3-71, a preclinical drug candidate with CNS-penetrable mono-therapy that bridges treatment of cognitive impairments with disease modifications; ANAVEX 1-41, a sigma-1 agonist for neuroprotective application; and ANAVEX 1037 for the treatment of prostate cancer. Anavex Life Sciences Corp. was founded in 2006 and is based in New York, New York.

4 Employees
Last Reported Date: 12/29/14
Founded in 2006

anavex life sciences corp (AVXL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $640.0K
Compensation as of Fiscal Year 2014.

anavex life sciences corp (AVXL) Key Developments

Anavex Life Sciences Corp. Announces Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS

Anavex Life Sciences Corp. announced dosing of the first patient in the Phase 2a clinical trial of ANAVEX 2-73 and ANAVEX PLUS, which are being developed as an oral therapy and oral drug combination for the potential treatment of Alzheimer's disease. In preclinical studies, ANAVEX 2-73 was shown to prevent, halt and/or reverse Alzheimer's disease by targeting sigma-1 and muscarinic receptors. The drug therapeutic showed no serious adverse events in a successfully completed Phase 1 human study. In this multicenter Phase 2a adaptive clinical trial of ANAVEX 2-73 and ANAVEX PLUS, at least 32 mild to moderate Alzheimer's patients will be enrolled and they will be able to receive the study drug for up to 26 weeks. The primary objective of the trial is to evaluate the maximum tolerated dose of ANAVEX 2-73 in these patients. Additional trial objectives include dose response, bioavailability, cognitive efficacy and the relationship of ANAVEX 2-73 as an add-on therapy to donepezil, the current standard of care.

Anavex Life Sciences Corp. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 through Jan-14-2015

Anavex Life Sciences Corp. Presents at 8th Annual OneMedForum 2015, Jan-12-2015 through Jan-14-2015. Venue: San Francisco Marriott Marquis, Parc 55 Wyndham, Union Square, San Francisco, California, United States. Presentation Date & Speakers: Jan-13-2015, Christopher U. Missling, Chairman, Chief Executive Officer, President, Chief Financial Officer, Treasurer, Secretary and Member of Scientific Advisory Board.

Anavex Life Sciences Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015

Anavex Life Sciences Corp. Presents at 33rd Annual J.P. Morgan Healthcare Conference, Jan-12-2015 . Venue: Westin St. Francis Hotel, San Francisco, California, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXL:US $0.19 USD +0.004

AVXL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXL.
View Industry Companies
 

Industry Analysis

AVXL

Industry Average

Valuation AVXL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 44.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANAVEX LIFE SCIENCES CORP, please visit www.anavex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.